Dawnrays Pharmaceutical Holdings Ltd. (HK:2348) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dawnrays Pharmaceutical Holdings Ltd. reports a significant increase in profit and earnings per share during the first half of 2024, despite a decrease in revenue and gross profit compared to the same period in 2023. The company’s profit before tax surged by 70.2% and the earnings per share soared by 92.5%, reflecting a robust growth in profitability. The interim dividend per share remains stable at HK$0.015.
For further insights into HK:2348 stock, check out TipRanks’ Stock Analysis page.